Treatment of Age-Related Macular Degeneration with Pluripotent Stem Cell-Derived Retinal Pigment Epithelium

Curr Eye Res. 2020 Mar;45(3):361-371. doi: 10.1080/02713683.2019.1691237. Epub 2019 Nov 28.

Abstract

Retinal pigment epithelium (RPE) degradation is central to the onset and progression of age-related macular degeneration (AMD), a growing and currently incurable form of blindness.Due to its key role in maintaining the retinal structure and homeostasis, cell replacement of the RPE monolayer has emerged as a promising therapy to rescue visual acuity in AMD patients.Thanks to the tremendous progress of pluripotent stem cell technologies over the last decade, a potentially unlimited new source for RPE transplantation has reached clinical trials. This review summarizes the methods by which pluripotent stem cell-based RPE cells are produced for transplantation, the delivery methods currently being adopted and the latest clinical outcomes with regard to the treatment of AMD.

Keywords: Age-related macular degeneration; cell therapy; pluripotent stem cells; regenerative medicine; retina; retinal pigment epithelium; stem cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Progression
  • Humans
  • Macular Degeneration / pathology
  • Macular Degeneration / therapy*
  • Retinal Pigment Epithelium / pathology*
  • Stem Cell Transplantation / methods*
  • Visual Acuity*